US Court Orders FDA to Reconsider E-Cigarette Sales Applications

Aug.25.2022
US Court Orders FDA to Reconsider E-Cigarette Sales Applications
US court orders FDA to reconsider rejection of six companies' e-cigarette applications, causing conflict with Washington, DC.

The United States federal appeals court has ruled that the Food and Drug Administration (FDA) must reconsider its decision to deny six companies permission to sell e-cigarette products. The ruling has caused a conflict between the court and Washington, D.C. The FDA has declined to comment on the decision.


Attorney Jerad Najvar of the Najvar law firm, representing e-cigarette liquid manufacturers Diamond Vapor, Union Street Brands, Vapor Unlimited LLC, and Johnny Copper LLC, stated that the FDA's belief that it can simply dismiss marketing plan review reports is incorrect. He explained that the agency mistakenly believes that his clients' liquid products have the same youth appeal as pre-filled liquid cartridges. The lawyer for Pop Vapor Co, the remaining company, did not immediately respond.


Electronic cigarettes deliver nicotine through the vaporization of liquid rather than the combustion of tobacco. In 2016, the US Food and Drug Administration determined that electronic cigarettes are subject to their regulation, just like traditional tobacco products, and allowed manufacturers to apply for approval before 2020.


Last autumn, these six companies petitioned with the 11th Circuit Court to review the FDA's denial of their applications to market various flavored e-cigarettes and liquids. These were among the over 55,000 such products that the agency rejected last year.


Chief Justice William Pryor and Circuit Judge Andrew Brasher jointly stated that the FDA's reasoning was due to "a federal district court judge refusing to hear arguments from the defendant regarding their reform plans or their impact on their family, because the judge, based on their experience, found these things to be irrelevant.


Circuit judge Robin Rosenbaum, who holds a dissenting opinion, stated that sending the case back to the US Food and Drug Administration would be "futile".


Statement:


This article is compiled from third-party information and is intended for industry exchange and learning purposes only.


This article does not represent the views of 2FIRSTS, and 2FIRSTS is also unable to confirm the authenticity and accuracy of the article's content. The compilation of this article is intended for industry exchange and research purposes only.


Due to limitations in the level of translation, the compiled article may not accurately convey the original meaning. Please refer to the original article for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on any domestic, Hong Kong, Macao, Taiwan, and foreign-related statements and positions.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.